Helixgate https://validator.w3.org/feed/docs/rss2.html FDA raises bar for foreign site inspections as China trials surge Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts New Spectrometry Technique Could Aid Formulation Development UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy Fortrea boosts early-phase CRO platform with $45M acquisition of Worldwide division Follow the money: How funding announcements can help identify jobs before they’re posted UniQure files for FDA, UK approval of first gene therapy for Huntington’s disease Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals Biopharma reverse mergers rise 1,600% in Q3 to rival IPOs Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails STAT+: ADA review of members’ expulsion denies group censored opinions, called in police Opinion: Diabetes association CEO: What an independent review says happened at the ADA’s controversial June conference Single-Cell Striatum Atlas Reveals Neurological Disorder Vulnerabilities Advanced Imaging Technique Reveals Immune Cell Metabolic States in Blood Samples STAT+: House votes to temporarily block Trump plan to politicize federal grants Opinion: I’m a reproductive psychiatrist. The Lindsay Clancy trial will cause terrible damage to my field Mid-cap biotechs join Trump’s latest round of drug pricing deals Roche finds another oncology gem in Asia with $1.5B B cell disease partnership GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality ArsenalBio sacrifices ‘majority’ of staff in pivot to in vivo CAR T 9 midsize drugmakers climb aboard Trump’s MFN train Why G‑quadruplex biology is back and what it means for MYC‑driven cancers A pervasive RT–qPCR artifact inflates RNA knockdown by RNA-targeting CRISPR Spatial Transcriptomics Tools May Link Tumor Organization to Treatment Response Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns New guidelines on migraine prevention reflect increasing options for patients Trump strikes nine more deals with drugmakers to lower prices Single-Use Comes of Age–What Comes Next? Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events FDA OKs Takeda, Protagonist drug for rare blood cancer STAT+: Can buying a drug patent application be seen as a bid to prolong a monopoly? STAT+: GLP-1 drugs are almost single-handedly forcing employers to reconsider workers’ health care STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis ESC: Alnylam’s next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split Deal-hungry Lilly strikes up to $2.9B immuno play for Merida Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity Four scientists awarded $3m for tau-driven disease research BMS’ neuro renaissance was built on back of Celgene mega-merger China poses increasing security risk as US biotech innovation edge erodes Macropinocytosis-mediated recyclable LYTACs (McR-TACs) for receptor-independent protein degradation StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua Researchers unveil sustainable spirulina solution to vitamin B12 deficiency STAT+: A Novartis drug cut inflammation. Can it improve heart outcomes?  Home